Artelo Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTL research report →
Price Chart
About the company
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.
- CEO
- Gregory D. Gorgas
- IPO
- 2019
- Employees
- 7
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on ARTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.34M
- P/E
- -0.05
- Fwd P/E
- 0.03
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.21
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -519.09%
- ROIC
- -219.36%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,404,000
- Net Income
- $-12,879,000-31.1%
- EPS
- $-49.23-438.1%
- OCF Growth
- -2.0%
- FCF Growth
- -2.0%
- 52W High
- $179.19
- 52W Low
- $3.41
- 50D MA
- $5.85
- 200D MA
- $25.29
- Beta
- -0.07
- RSI (14)
- 37
- Avg Volume
- 486.66K
No earnings-call transcripts are available for ARTL yet.
- Free Float
- 62.4%
- Shares Outstanding
- 387.28K
- Float Shares
- 241.50K
of shares held by institutions
10 13F filers
Buy/sell ratio 0.72. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 66.34K | ▲ 53.26K |
| Vanguard Group Inc | 14.03K | 0 |
| Geode Capital Management, LLC | 13.86K | ▲ 13.86K |
| Stonex Group Inc. | 12.40K | ▲ 12.40K |
| Vanguard Capital Management LLC | 10.13K | 0 |
| Tower Research Capital LLC (Trc) | 8.44K | ▲ 5.61K |
| Vanguard Fiduciary Trust Co | 3.14K | 0 |
| Ubs Group AG | 2.80K | ▲ 2.80K |
| Td Waterhouse Canada Inc. | 2 | ▲ 2 |
| Rothschild Investment LLC | 2 | 0 |
| Danske Bank A/S | 1 | ▲ 1 |
| Cwm, LLC | 1 | ▲ 1 |
Held by 5 ETFs
Biggest fund positions in ARTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 26 | MATSUI CONNIE | other | 136 |
| Jul 17, 26 | Blayney Douglas | other | 136 |
| Jul 17, 26 | Reyes Gregory | other | 136 |
| Jul 17, 26 | EMANUELE ROBERT MARTIN | other | 136 |
| Jul 17, 26 | Kelly Steven | other | 136 |
| Jul 17, 26 | FAVORITO TAMARA A | other | 136 |
| Jan 30, 26 | MATSUI CONNIE | other | 292 |
| Jan 30, 26 | Blayney Douglas | other | 292 |
| Jan 30, 26 | EMANUELE ROBERT MARTIN | other | 292 |
| Jan 30, 26 | Kelly Steven | other | 292 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTL coverage
Recent articles, reports, and earnings notes.
No research on ARTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTL report →Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September
defenseworld.net · Oct 1
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
globenewswire.com · Sep 23
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
globenewswire.com · Sep 16
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 36.9% in August
defenseworld.net · Aug 31
Artelo Biosciences Announces Reverse Stock Split
globenewswire.com · Aug 27
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
globenewswire.com · Aug 20
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
globenewswire.com · Aug 17
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
globenewswire.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.